Cart
sales@molnova.com
HBED
CAS No. 35998-29-9
HBED( CHEL II | CHEL-II | CHELII )
Catalog No. M27988 CAS No. 35998-29-9
HBED is an iron chelator and can be used in research on the treatment of chronic iron overload and acute iron poisoning.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 37 | In Stock |
|
| 10MG | 38 | In Stock |
|
| 25MG | 61 | In Stock |
|
| 50MG | 85 | In Stock |
|
| 100MG | 123 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 299 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHBED
-
NoteResearch use only, not for human use.
-
Brief DescriptionHBED is an iron chelator and can be used in research on the treatment of chronic iron overload and acute iron poisoning.
-
DescriptionHBED is an iron chelator and can be used in research on the treatment of chronic iron overload and acute iron poisoning.
-
In Vitro——
-
In Vivo——
-
SynonymsCHEL II | CHEL-II | CHELII
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number35998-29-9
-
Formula Weight388.42
-
Molecular FormulaC20H24N2O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC1=CC=CC=C1CN(CCN(CC(O)=O)CC2=CC=CC=C2O)CC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hatanaka, Y., Tsukiji, M., Itoh, A., et al. Selective adsorption of immunoglobulin G and immunoglobulin M from plasma without adsorption of fibrinogen by using thienyl amino acids as ligandsJ. Chromatogr.4(6)1000190(2013)
molnova catalog
related products
-
Mycophenolate Mofeti...
Mycophenolate Mofetil(RS 61443) is a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase I/II with IC50 of 39 nM and 27 nM, respectively.
-
IP3R - derived Pepti...
IP3R - derived Peptide
-
Acetyl-Hirudin (54-6...
Acetyl-Hirudin (54-65) (sulfated) is a acetyl-fragment of Hirudin which binds directly to thrombin-rHCII(L444R) and disrupts interactions between the N-terminal acidic domain of rHCII and anion-binding exosite I of thrombin that serves to stabilize the complex.
